Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease
Figure 3
Immunostaining for CFTR in the liver of control and pioglitazone-treated PCK rats after 14 weeks of drug treatment. Control (a) or 20 mg/kg BW pioglitazone-treated (b) liver sections were immunostained for CFTR with mAb 596 CFTR antibody followed by a gold-labeled secondary antibody. Shown in both panels is the CFTR staining (spherical dots) in the apical membrane sections of epithelial cells surrounding the bile duct cysts. 49 000x magnification.
